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Should you treat carriers 
of pharyngeal group A strep?
Evidence-based answer
The jury is out as to whether you should 
treat asymptomatic carriers of group A 
streptococci (GAS), because no studies 
specifi cally address the issue. In addition, 
many patients are unlikely to care about 
their carrier status, although they probably 
care about symptoms and treatment side 
effects. Nonetheless, you may want to 
consider treating GAS carriers under the 
following circumstances (strength of 
recommendation [SOR]: C, expert opinion): 
1.  recurrent pharyngitis without cough or 
congestion
2.  acute rheumatic fever or 
poststreptococcal glomerulonephritis 
outbreaks
3.  GAS pharyngitis outbreaks in a closed 
community
4.  family history of acute rheumatic fever
5.  multiple documented GAS pharyngitis 
episodes within a family over several 
weeks despite therapy
6.  excessive patient/family anxiety about 
GAS 
7.  all treatment options, except 
tonsillectomy, have been exhausted.
 Oral clindamycin for 10 days is 
probably the most effective treatment for 
carriers. A single dose of intramuscular 
penicillin plus 4 days of oral rifampin is 
also effective (SOR: C, 2 randomized 
controlled trials [RCTs]).
Clinical commentary
A case I won’t soon forget 
My most memorable encounter with GAS 
carriage involved a family of 5 when I was 
practicing in a small town. The youngest 
child, about 6 years of age, had recurrent, 
culture-positive GAS pharyngitis. I tested 
the family twice, but all cultures remained 
stubbornly negative. When the mother 
complained to the family veterinarian 
the next week about her son’s recurrent 
infections, the vet decided to culture the 
dog. The dog was positive, was treated, 
and the infections stopped!
 Be sure to culture all household 
contacts before prescribing antibiotics. 
Patients (and parents) want to break the 
cycle and avoid future infections, so they 
are motivated to make sure that everyone 
is cultured. Providers and staff must be 
fl exible in order to accomplish this.
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❚ Evidence summary
As many as 25% of patients with GAS 
pharyngitis remain culture-positive after 
an adequate regimen of antibiotic ther-
apy and are deemed GAS carriers.1 Ap-
propriate screening and management of 
asymptomatic carriers continues to cause 
confusion.
My most memorable
encounter with 
GAS carriage? 
When I learned a 
family dog was 
probably to blame 
for a young boy’s 
recurrent infections
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Routine treatment 
is usually unnecessary
The Infectious Diseases Society of Amer-
ica (IDSA) considers GAS carriers at low 
risk for developing complications and 
spreading infection to close contacts.2 
The 2002 IDSA practice guidelines rec-
ommend against routine screening for 
and treatment of GAS carriage except 
under the circumstances (2 through 7) 
outlined in the evidence-based answer.2 It 
may be reasonable to treat patients whose 
carrier status is unknown when they have 
a second case of pharyngitis. For known 
GAS-positive patients, however, repeated 
episodes of pharyngitis over months or 
years should raise suspicion of intercur-
rent viral pharyngitis rather than true 
GAS pharyngitis. 
When you should 
consider routine treatment
Some experts practicing in areas with 
a high prevalence of acute rheumatic 
fever take a different position: They fa-
vor routine treatment of patients with 
active pharyngitis and a positive throat 
culture, even if the patient is a known 
GAS carrier.3 
No clear consensus on prophylaxis
In 1995, the Centers for Disease Control 
and Prevention convened a consensus 
group to address the issue of prophylaxis 
for people exposed to GAS-positive car-
riers, but the consensus group failed to 
reach a defi nitive conclusion.4 
Clindamycin works; penicillin + 
rifampin is also effective
Most RCTs investigating effective an-
tibiotic treatment of GAS target cases 
of acute pharyngitis. A wide variety of 
antibiotics have been studied, including 
cefadroxil, amoxicillin, amoxicillin/cla-
vulanate, cefuroxime, azithromycin, cef-
prozil, and cephalexin. We evaluated 41 
of 43 studies of treatment of acute GAS. 
Only 2 RCTs specifi cally address effec-
tive antibiotic regimens for treating GAS 
carriers. 
The most recent study demonstrated 
a signifi cantly greater eradication rate 
with oral clindamycin than penicillin 
plus rifampin (P<.025).5 Compared with 
penicillin plus rifampin after 3 weeks 
of therapy, the number needed to treat 
(NNT) for clindamycin was 4.5 
An older study found intramuscular 
penicillin plus 4 days of oral rifampin su-
perior to intramuscular penicillin alone 
(P<.005) or no treatment at all (P<.0005) 
for eradicating GAS in carriers.1 Compared 
with placebo after 3 weeks of therapy, the 
NNT for penicillin plus rifampin was 2.1
The IDSA recommends a 10-day 
course of amoxicillin/clavulanate as an 
alternative treatment option.2
Recommendations
The 2006 Red Book: Report of the Com-
mittee on Infectious Diseases notes 6 pos-
sible indications for treating GAS carriers; 
they’re nearly identical to circumstances 
2 through 7 in the evidence-based an-
swer.6 The Red Book also acknowledg-
es several treatment options, including 
clindamycin, amoxicillin, azithromycin, 
and penicillin plus rifampin. A 10-day 
course of oral clindamycin, however, is 
the therapy of choice.6 ■
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